TY - JOUR T1 - Usefulness of Duloxetine for Paclitaxel-Induced Peripheral Neuropathy Treatment in Gynecological Cancer Patients JF - Anticancer Research JO - Anticancer Res SP - 359 LP - 363 VL - 35 IS - 1 AU - AKIKO OTAKE AU - KIYOSHI YOSHINO AU - YUTAKA UEDA AU - KENJIRO SAWADA AU - SEIJI MABUCHI AU - TOSHIHIRO KIMURA AU - EIJI KOBAYASHI AU - AKI ISOBE AU - TOMOMI EGAWA-TAKATA AU - SHINYA MATSUZAKI AU - MASAMI FUJITA AU - TADASHI KIMURA Y1 - 2015/01/01 UR - http://ar.iiarjournals.org/content/35/1/359.abstract N2 - Aim: The present study aimed at evaluating the usefulness and adverse effects of duloxetine treatment for paclitaxel-induced peripheral neuropathy in gynecological cancer patients. Patients and Methods: Medical records of gynecological cancer patients treated with duloxetine were retrospectively studied to evaluate the drug's efficacy for paclitaxel-induced peripheral neuropathy. Results: Results from 25 patients showed that an improved response was observed in 14 (56%). By univariate and multivariate analysis, the patient's age, tumor origin, regimen of chemotherapy, accumulated doses of paclitaxel or carboplatin, previous medication, maintenance dosage and timing of treatment with duloxetine were found not to be associated with the effectiveness of duloxetine treatment. Adverse effects with duloxetine were mild and well-tolerated. Conclusion: As an option, duloxetine can be effectively used for paclitaxel-induced peripheral neuropathy in patients with gynecological cancers, irrespective of patients' age, origin of the tumor, regimen of chemotherapy, or previous medication. ER -